Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)

Stopped early · Phase 1/Phase 2

Conditions studied: Acute Myelogenous Leukemia

In brief

This is a phase I, single-arm, open-label, multi-center study of rising doses of Troxatyl™ whose purpose is to determine the safety, tolerance, and pharmacokinetics, and to establish the recommended infusion schedule of Troxatyl™.

Key facts

Study ID
NCT00104468
Run by
SGX Pharmaceuticals, Inc.
People needed
50
Starts
2003-04-01
Expected to finish
2007-06-01
Last updated by the study team
2008-01-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.